FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression

Pharmaceutical Research

Volumn 22, Issue 2, 2005, Pages 193-199

  Lamprecht, Alf ^a,b,c   Yamamoto, Hiromitsu ^a   Ubrich, Nathalie ^b   Takeuchi, Hirofumi ^a   Maincent, Philippe ^b   Kawashima, Yoshiaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b INSERM   (France)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Colitis; Colon delivery; Inflammatory bowel disease; Microspheres; Tacrolimus

Indexed keywords

EUDRAGIT; MICROSPHERE; MYELOPEROXIDASE; POLYMER; TACROLIMUS; TRINITROBENZENESULFONIC ACID;

ARTICLE; COLITIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVITY; INFLAMMATION; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; CALCINEURIN; COLITIS; KIDNEY; MALE; MICROSPHERES; RATS; RATS, WISTAR; TACROLIMUS;

EID: 16844372085     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-1186-2     Document Type: Article

References (29)

1. D. R. Friend. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 12:591-603 (1998).
2. M. Robinson. Medical therapy of inflammatory bowel disease for the 21st century. Eur. J. Surg. Suppl. 582:90-98 (1998).
3. A. G. Fraser, T. R. Orchard, and D. P. Jewell. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50:485-489 (2002).
4. O. H. Nielsen, B. Vainer, and J. Rask-Madsen. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol Ther. 15:1699-1708 (2001).
5. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens. A. Carbonez, and P. Rutgeerts. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348:601-608 (2003).
6. N. Matsuhashi, A. Nakajima, K. Watanabe, Y. Komeno, A. Suzuki, S. Ohnishi, M. Omata, K. Kondo, Y. Usui, J. I. Iwadare, T. Watanabe, H. Nagawa, and T. Muto. Tacrolimus in corticoid-resistant ulcerative colitis. J. Gastroenterol. 35:655-657 (2000).
7. K. Fellermann, D. Ludwig, M. Stahl, T. David-Walek, and E. F. Stange. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 93:1860-1866 (1998).
8. M. E. Cardenas, D. Zhu, and J. Heitman. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr. Opin. Nephrol. Hypertens. 4:472-477 (1995).
9. T. Wang, B. Y. Li, P. D. Danielson, P. C. Shah, S. Rockwell, R. J. Lechleider, J. Martin, T. Manganaro, and P. K. Donahoe. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 86:435-444 (1996).
10. Q. Su, L. Weber, M. Le Hir, G. Zenke, and B. Ryffel. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren. Physiol. Biochem. 18:128-139 (1995).
11. W. F. Finn. FK506 nephrotoxicity. Ren. Fail. 21:319-329 (1999).
12. D. R. Friend. Colon-specific drug delivery. Adv. Drug Del. Rev. 7:149-199 (1991).
13. A. Rubinstein. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12:101-149 (1995).
14. P. J. Watts, L. Barrow, K. P. Steed, C. G. Wilson, R. C. Spiller, C. D. Melia, and M. C. Davies. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int. J. Pharm. 87:215-221 (1992).
15. F. H. Hardy, S. S. Davis, R. Khosla, and C. S. Robertson. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int. J. Pharm. 48:79-82 (1988).
16. H. Nakase, K. Okazaki, Y. Tabata, S. Uose, M. Ohana, K. Uchida, Y. Matsushima, C. Kawanami, C. Oshima, Y. Ikada, and T. Chiba. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292: 15-21 (2000).
17. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Maincent, Y., Kawashima Y, and C.M. Lehr. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299:775-781 (2001).
18. Z. Hu, T. Shimokawa, T. Ohno, G. Kimura, S. S. Mawatari, M. Kamitsuna, Y. Yoshikawa, S. Masuda, and K. Takada. Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer, P-4135F. J. Drug Target. 7:223-232 (1999).
19. Y. I. Jeong, Y. R. Prasad, T. Ohno, Y. Yoshikawa, N. Shibata, S. Kato, K. Takeuchi, and K. Takada. Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine. J. Pharm. Pharmacol. 53:1079-1085 (2001).
20. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima. Design of pH-sensitive microspheres for the colon delivery of FK506. Eur. J. Pharm. Biopharm. 58:37-43 (2004).
21. G. Hartmann. C. Bidlingmaier, B. Siegmund. S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H. A. Lehr, and S. Endres. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292:22-30 (2000).
22. R. González, S. Rodríguez, C. Romay, O. Ancheta, A. González, J. Armesto, D. Remirez, and N. Merino. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol. Res. 39:55-59 (1999).
23. J. E. Krawisz, P. Sharon, and W. F. Stenson. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350 (1984).
24. A. Higa, G. W. McKnight, and J. L. Wallace. Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur. J. Pharmacol. 239:171-176 (1993).
25. H. Hoshino, H. Goto, S. Sugiyama, T. Hayakawa, and T. Ozawa. Effects of FK506 on an experimental model of colitis in rats. Aliment. Pharmacol. Ther. 9:301-307 (1995).
26. S. Aiko, E. M. Conner, J. A. Fuseler, and M. B. Grisham. Effects of cyclosporine or FK506 in chronic colitis. J. Pharmacol. Exp. Ther. 280:1075-1084 (1997).
27. A. Kagayama, S. Tanimoto, J. Fujisaki, A. Kaibara, K. Ohara, K. Iwasaki, Y. Hirano, and T. Hata. Oral absorption of FK506 in rats. Pharm. Res. 10:1446-1450 (1993).
28. Y. Hashimoto, H. Sasa, M. Shimomura, and K. Inui. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm. Res. 15:1609-1613 (1998).
29. H. Sako, H. Nakashima, T. Sawada, and M. Fukui. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonie drug release in dogs. Pharm. Res. 13:594-598 (1996).